Sept. 2 - In an interview with the Houston Chronicle, Dr. Catherine Troisi answered questions about the COVID pandemic and the Delta variant.
Aug. 20 - Dr. Jennifer Whitaker and colleagues are recruiting participants for a second-generation booster COVID-19 vaccine trial to test investigational COVID-19 vaccines developed by Gritstone bio, Inc.
July 29 - A multidisciplinary team of researchers, including Drs. Maria Elena Bottazzi and Peter Hotez, is the first to show that combining yeast-expression technology and a novel adjuvant formulation produces a COVID-19 vaccine candidate that is effective against SARS-COV-2.
July 22 - Drs. B.V. Venkataram Prasad, Mary Estes and collaborators have isolated naturally occurring antibodies that recognized and neutralized many different norovirus variants. Information from this study could lead to new vaccine candidates and treatments for norovirus infection.
June 22 - Dr. Robert Atmar was interviewed by CBS national news about the COVID vaccine booster trial that is underway.
May 29 - Dr. Jennifer Whitaker is the principal investigator of the Baylor site of a multicenter Phase 1 clinical trial to evaluate the safety, tolerability and immune response for different doses of Gritstone Oncology's COVID-19 vaccine candidate. This second-generation trial has been designed with the goal of providing protection against emerging variants of SARS-CoV-2.
May 13 - Baylor College of Medicine will serve as the lead site of the new Texas Development Center for AIDS Research (D-CFAR). Funded through a grant from the NIH, D-CFAR is a collaboration of Baylor, The University of Texas Health Science Center at Houston and the Texas Biomedical Research Institute in San Antonio. Dr. Andrew Rice is the co-director for Baylor and the director of the D-CFAR Developmental Core.
April 26 - Biological E. Limited to begin Phase III clinical trials of a COVID-19 vaccine candidate developed by a team co-led by Drs. Maria Elena Bottazzi and Peter Hotez.
March 30 - An article in "From the "Labs" describes the work of a group led by Dr. Anthony Maresso in using phages to prevent infection before it happen.
March 8 - Dr. Robert Atmar commented on the more contagious COVID variant spreading in Houston for local media.
Feb. 11 - Dr. Hana El Sahly provided advice on what you need to know after getting the COVID-19 vaccine.
Feb. 9 - Dr. Anthony Maresso and colleagues have identified a novel strategy using phage to anticipate the location of bacteria providing a mechanism to eliminate bacteria prior to infection.
Feb. 4 - Drs. Pedro A. Piedra, Brian Gilbert, Lynn Zechiedrich, and colleagues have reported that the duration of the antibody response varies in adults with RSV.
Feb. 1 - Dr. Kristen Engevik, postdoctoral associate in Dr. Joseph Hyser’s lab, was the winner of the American Journal of Physiology “Cell-ebrating HeLa” competition with this image of immunofluorescent HeLa cells.
Jan. 15 - The Vaccine and Treatment Evaluation Unit has been selected to participate in the Phase 3 clinical trial to evaluate the safety and effectiveness of Novavax's COVID-19 vaccine candidate. Dr. Jennifer Whitaker is a co-principal investigator of the Baylor site.
Dec. 24 - In a podcast, Dr. Hana El Sahly, a lead investigator for the Moderna COVID-19 vaccine phase 3 trial, explains the COVID-19 RNA vaccines, including how they work, the differences between the Pfizer and Moderna vaccines, and why wearing masks is still necessary.
Dec. 14 - Dr. Pedro Piedra commented on an antibody test survey conducted by Baylor, in partnership with the Houston Health Department, Rice University, and the CDC, showing that the number of Houstonians who have been infected with the COVID-19 virus could be four times higher than previously reported.
Dec. 8 - Dr. Joseph Hyser and colleagues discovered aberrant calcium dynamics in both infected and uninfected cells, explaining how a few rotavirus can cause severe gastrointestinal disease.
Oct. 6 - Dr. Susan Rosenberg was awarded the National Institutes of Health Director’s Pioneer Award, her second time winning the prestigious honor.
Sept. 24 - Dr. Anthony Maresso and colleagues, in partnership with the Houston Health Department and Rice University, have determined that testing Houston’s wastewater for SARS-CoV2 provides a means to predict an outbreak.
Sept. 22 - A study by Dr. Mary Estes and colleagues showed that not all human norovirus strains are created equal in their sensitivity to interferon.
Sept. 18 - Dr. Sarah Blutt and her group were one of two Baylor teams among five selected by the Translational Research Institute for Space Health to receive funding for their project entitled "Use of Microbial Based Countermeasures to Mitigate Radiation Induced Intestinal Damage."
Sept. 3 - Dr. Pedro Piedra discussed the start of a COVID-19 antibody survey to determine the prevalence of people who have been infected with the virus in Houston with local media.
The Vaccine and Treatment Evaluation Unit at BCM, headed by Dr. Hana El Sahly, was one of approximately 90 sites selected to participate in the Phase 3 clinical trial for Moderna’s investigational mRNA-1273 vaccine to evaluate the efficacy of the vaccine at preventing COVID-19 disease. Dr. El Sahly also serves as a national co-principal investigator of the trial.
July, 7 - In an interview with the Houston Chronicle, Dr. Joseph Petrosino provided insight into what a potentially more contagious strain of COVID-19 means for the Houston area.
A study of a slow-growing rotavirus mutant by Dr. Mary Estes and colleagues revealed early steps of viral assembly.
April 28 - Development of a vaccine for SARS-CoV-2 is underway, co-led by Dr. Maria Elena Bottazzi and Dr. Peter Hotez, building on their experience gained through work on a SARS vaccine.
Dr. Lynn Zechiedrich was honored on Faculty Awards Day as a 2020 recipient of the Barbara and Corbin J. Robertson Jr. Presidential Award for Excellence in Education.
Dr. Andrew Rice was awarded one of nine grants from BCM and the University of Houston, as part of a pilot program resulting from a 2019 Memorandum of Understanding between the two institutions for a project called “Discovery of pharmacological modulators for NEAT1 IncRNA and reactivation of latent HIV-1.”, along with UH collaborator Dr. Qin Feng.
Dr. Buck Samuel served as an International Teaching Program Fellow at Tel Aviv University, teaching a course on the Microbiome in Health and Disease.
Viral gastroenteritis around the world causes 200,000 deaths globally each year. Mary Estes talks about her work on two gastroenteritis-causing viruses, rotavirus and norovirus, and tells the story of her discovery of the first viral enterotoxin. She also describes how noroviruses have changed from human volunteer studies to studies using “miniguts,” a system now used with many enteropathogenic microorganisms.
Jan. 28 - Dr. Mary Estes and colleagues describe findings that shed light on the role of bile acids in stimulating norovirus infection.
The Vaccine and Treatment Evaluation Unit (VTEU) has received a seven-year renewal grant from the National Institutes of Health and will join the new Infectious Diseases Clinical Research Consortium. Baylor’s unit is led by Dr. Hana El Sahly. Dr. Robert Atmar is a member of the newly formed executive management team.
Dec. 19 - An analysis of samples available through the TEDDY study, by a team of investigators including Dr. Richard Lloyd, has revealed unexpected viral behavior linked to type 1 diabetes in high-risk children.
Nov. 12 - Dr. Joseph Hyser and colleagues reported that Tulane virus, a model system for human noroviruses, takes over cellular calcium signaling to replicate.
Dr. Anthony Maresso recently published the textbook “Bacterial Virulence: A Conceptual Primer".
Dr. Mary Estes was honored with a 2020 Lifetime Achievement Award from the American Academy of Microbiology for sustained contributions to the microbiological sciences.
Aug. 15 - A team led by Dr. Larry Donehower conducted the most comprehensive study of TP53 mutations to better understand the processes leading to the inactivation of this important tumor suppressor gene.
Co-principal investigators Drs. Joseph Petrosino and Richard Gibbs were awarded a grant of up to $19.5 million from the NIH Genomic Centers of Infectious Diseases Program to study mucosal infection through the use of genomics and organoid model systems.
In celebration of Woman's History Month, BCM highlights the research of Baylor Women of Science, including the work of Drs. Janet Butel, Mary Estes, and Rebecca Rico-Hesse.
As part of BCM's "Ask Me About My Research" series, Dr. Paul Ling describes his work on herpesvirus in elephants to a young guest.
Drs. Mary K. Estes, Jeanette M. Criglar, B V Venkataram Prasad and colleagues have discovered that a cellular protein called CK1α is required to assemble rotavirus factories. See Image of the Month: Assembling a rotavirus factory.
A study by Drs. Sasirekha Ramani, Mary K. Estes, and colleagues showed that sugars in mother’s milk influence neonatal rotavirus infection.
Dr. Lawrence Donehower and colleagues have shown that the PPM1D gene can confer blood cells exposed to the chemotherapy agent cisplatin a survival advantage that might favor the development of leukemia years later.
Dr. Joseph Petrosino and colleagues have identified distinct stages in infant microbiome development. Published in the journal Nature, their results are based on extensive analysis of data collected from a cohort of participants involved in the TEDDY diabetes study (The Environmental Determinants of Diabetes in the Young).
Dr. Betty Slagle and her team have been awarded one of the first grants from Baylor for precision medicine and population health topics for the project "Human liver organoid infection model for hepatitis B virus."
Research by Dr. Gretchen Diehl and colleagues reveals how the intestinal microbiota interact with the immune system to limit a damaging inflammatory response.
A study by Dr. Rebecca Rico-Hesse and colleagues showed that mosquito saliva alone can induce a diverse and complex immune response.
Dr. Margaret Conner was a guest scientist on a segment of the NPR program Science Friday about the relationship between immunoglobulin A and the microbiome.
Dr. Peter Hotez has been elected to the American Academy of Arts and Sciences, one of the nation's most prestigious honorary titles.
Dr. Paul Ling and colleagues identified T cell immune responses directed against elephant endotheliotropic herpesvirus, which could lead to the development of an effective vaccine for this deadly disease.
Dr. Lynn Zechiedrich gave a presentation at the annual meeting of the National Academy of Inventors in Washington D.C. where she was inducted as a 2017 Fellow.
Years of basic research on rotavirus and vaccine candidate virus-like particles by Dr. Mary Estes, Dr. Sue Crawford, Dr. Margaret E. Conner, Dr. Sarah E. Blutt and other leads to a licensing agreement with ImmuCell and the development of a product to protect newborn calves from the diarrhea-causing disease.